Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > CG Oncology is worth 7x more than us

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Jul 13, 2023 12:57pm

487 Views

Post# 35539629

RE:RE:RE:RE:RE:CG Oncology is worth 7x more than us

2024 for final jv news, most probably end of Q1/early Q2.

2023 was to initiate the process. Board has just recently initiated that process.

It won't be MERCK as Merck seems to be the partner of ImmunityBio given that this is a combo involving BCG. And that Merck is also doing a combo with CG Oncology involving Keytruda. So clearly, we should interest a Merck's competitor and Roche is a fairly legitimate jv candidate given its interest (and setbacks) in the bladder indication. Moreover, Roche also has an interest in the GBM indications and also has an interest in the lung indication, as previously documented.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages